Background: Chronic rhinosinusitis (CRS) is a common condition which affects the quality of life of millions of patients worldwide and has a significant impact on health-care resources. While Staphylococcus aureus bacterial biofilms play an important role in this disease, antimicrobial therapy is rarely effective and may promote antibiotic resistance. Thus, development of novel biofilm-targeting and antibiotic-sparing therapies is highly desirable and urgently required.
Introduction
Chronic rhinosinusitis (CRS) with or without nasal polyps (CRSwNP and CRSsNP, respectively) is a chronic inflammatory condition of the nose and paranasal sinuses 1 presenting with symptoms such as nasal blockage, rhinorrhoea, facial pain or pressure, reduction, or loss of smell. It is one of the most common conditions encountered in medicine. 1 Despite a wide range of medical therapies and surgical procedures undertaken to treat CRS, the condition remains recalcitrant in a large subset of patients, 2,3 affecting quality of life 4 and increasing health-care expenditure. 5 Thus, there is a large unmet need for the development of new therapeutic strategies for this condition aimed at reducing reliance on antibiotics, steroids, and invasive surgical procedures as well as improving clinical outcomes following endoscopic sinus surgery.
Biofilm is an association of microorganisms in which microbial cells adhere to each other on a living or nonliving surfaces within a self-produced matrix of extracellular polymeric substance. Staphylococcus aureus biofilms are known mediators of the inflammatory reaction in CRS, 1, 6 and are associated with more severe preoperative disease, persistence of ongoing mucosal inflammation and poor postsurgical outcomes. 7 S. aureus, a Gram-positive, biofilm-forming bacterium, has previously been detected in sinus mucosal tissues of CRS patients. 8 A recent observation of S. aureus intracellular localization within mast cells of nasal polyps 9 suggests possible presence of bacterial reservoirs within host tissues-a potential future therapeutic target. It is estimated that 20% of S. aureus clinical isolates are methicillin-resistant S. aureus (MRSA) and exhibit substantial elevated levels of multidrug resistance as compared with non-MRSA strains. 10 It is likely that bacterial biofilms within the sinonasal mucosa mediate a continuing inflammatory reaction leading to early disease recurrence, development of chronicity, and recalcitrance. 11 With similar mechanisms in other chronic respiratory infections, 12 conventional antimicrobial therapy is rarely effective in eradication of CRS bacterial biofilms and may lead to selection for antibiotic resistance. 13, 14 As such, the development of alternative biofilm-targeted therapies is both highly desirable and urgently required for a range of biofilm-mediated chronic respiratory conditions including CRS, otitis media, chronic obstructive pulmonary disease, primary ciliary dyskinesia, and cystic fibrosis. 15 Honey is one of the oldest known antimicrobials, dating back to ancient times where the Egyptians used it as a natural antibiotic and to treat skin infections. Manuka honey has long been used in the treatment of chronic wounds and leg ulcers. 16 It is thought that its antibacterial properties are mediated by a combination of hydrogen peroxide accumulation through the inhibition of glucose oxidase, acidity, high osmolarity, and the presence of methylglyoxal. 17, 18 The minimum inhibitory concentrations (MICs) do vary depending on the bacterial strains and source of the honey. Thus far, 2 studies have evaluated the clinical use of topical manuka honey in the nose, one in allergic fungal sinusitis, 19 and the other in active CRS with previous sinus surgery. 20 Both studies showed some therapeutic benefit in those patients receiving the manuka honey.
SurgihoneyRO TM (Matoke Holdings Ltd, UK), a bioengineered honey comprising gamma irradiated honey and glucose oxidase from Aspergillus niger, 21 has previously been shown to have antibiofilm activity against a range of wound pathogens 22 and the opportunistic pathogen nontypeable Haemophilus influenza. 23 In the presence of water, glucose oxidase oxidizes glucose present in the natural honey. In the process, hydrogen peroxide, a reactive oxygen species, is released, leading to oxidation of DNA, proteins, and membrane lipids in bacteria. 24 Although addition of glucose oxidase enhances the antimicrobial activity of honey and reduces the effect of natural variability between different batches of honey on the efficacy of the final product, there is a need for a fully standardized, artificial product. Apart from providing a reproducible antimicrobial treatment, which could be used externally and internally, a synthetic formulation would save natural resources and be suitable for patients unable or unwilling to use animal productbased treatments. A synthetic honey-equivalent antimicrobial product was therefore developed which contains glucose oxidase and a substrate for the enzyme to provide antimicrobial activity but does not introduce substances such as proteins, minerals, and traces of pollen present in natural honey. The product, Synthetic ROþ, is sterile, has a pH of 7.04, and is composed of fructose (52% weight), glucose, (31%), citric acid/NaOH buffer (17%), and glucose oxidase (1000 ppm). 25 The aim of this study was to evaluate antibacterial activity of SurgihoneyRO TM and a novel synthetic honey-equivalent antimicrobial product against CRSrelated mucosal methicillin-sensitive S. aureus (MSSA) and MRSA strains. The reported findings underpin the proposed clinical development of a synthetic honeyequivalent antimicrobial product as a novel topical biofilm-targeted adjunctive therapy in chronic respiratory infections such as CRS.
Methods
All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the Southampton and South West Hampshire Research Ethics Committee (ref. 09/H0501/ 74). Informed consent was obtained from all participants.
Bacterial Strains and Growth Conditions
S. aureus strains used in this study were isolated from 12 individual CRSwNP patients and validated by the UK Public Health England Microbiology Services laboratory, Southampton. Five strains displayed methicillin-sensitivity (MSSA1-5) and 7 strains-methicillin-resistance (MRSA1-7). All strains were grown on Columbia blood agar plates (Oxoid, UK) for 18 hours at 37 C under a 5% CO 2 atmosphere. Single, representative colonies were resuspended in Brain Heart Infusion (BHI) broth (Oxoid) and used for further experiments upon reaching mid-exponential phase of growth.
Planktonic Growth
Engineered honey (SurgihoneyRO TM ) and the synthetic honey-equivalent product with and without glucose oxidase (Synthetic ROþ and Synthetic ROÀ, respectively) were prepared in BHI in clear flat-bottomed polystyrene 96-well plates (Corning Incorporated, USA) at a range of concentrations (0-383 g/L) previously used to investigate SurgihoneyRO treatment of planktonic nontypeable H. influenza. 23 For assessment of cell viability, scraped cell suspensions were briefly vortexed and then serial diluted for spot plating on Columbia blood agar plates. Plates were incubated for 18 hours at 37 C under a 5% CO 2 atmosphere for colony forming unit (CFU) enumeration. To assess total biofilm biomass, aliquots of the same cell suspensions were diluted 10-fold in BHI. Total biomass was measured by OD 595 on Jenway 6300 spectrophotometer (Cole-Parmer, UK) against a blank of sterile BHI.
Assessment of biofilm viability was also performed for a range of strains of S. aureus. Five methicillinsensitive (MSSA1-5) and 7 methicillin-resistant (MRSA1-7) strains were grown as described above, 2 wells per strain. At 48 hours, spent media were removed, biofilms were washed with HBSS, and either HBSS or 71 g/L Synthetic ROþ in HBSS was applied. After 24 hours, biofilms were washed, resuspended, serially diluted, and plated for CFU enumeration as described above. All assays were performed using 5 biological replicates.
Confocal Laser Scanning Microscopy
Mid-exponential planktonic cultures of S. aureus MSSA1 and MRSA1 grown in BHI were used to inoculate 35-mm untreated glass-bottom CELLview cell culture dishes ($1.0 Â 10 8 planktonic bacteria per well; Greiner Bio One, UK). Cultures were incubated under static conditions at 37 C with a 5% CO 2 atmosphere for 48 hours, replacing spent media with fresh BHI at 24 hours. At 48 hours, BHI was removed and biofilms were washed twice with HBSS. Cultures were treated with 71 g/L Synthetic ROþ in HBSS, 71 g/L Synthetic ROÀ in HBSS, or HBSS (2 treatment replicates per strain) and incubated under static conditions for 24 hours at 37 C with a 5% CO 2 atmosphere. After 48 hours, treatments were removed and the biofilms were washed twice with HBSS before staining with LIVE/DEAD Baclight Bacterial Viability Kit (Life Technologies, UK) as per manufacturer's instructions. Biofilms were examined using an inverted confocal microscope (Leica SP8; Leica Microsystems, UK) with 63Â oil immersion lens and sequential scanning of 2 lm sections. Images of 5 fields of view per sample were taken to determine average maximum biofilm thickness after 48 hours of treatment.
Hydrogen Peroxide Release
Hydrogen peroxide released by the Synthetic ROþ and ROÀ products was measured over 24 hours using a Fluorimetric H 2 O 2 Assay Kit (Sigma-Aldrich, UK) as per manufacturer's instructions. The products were diluted in HBSS to a concentration of 71 g/L (3 dilutions per product) and incubated at 37 C under a 5% CO 2 atmosphere for 24 hours. Samples were taken every 15 minutes for the first hour, every hour for 7 hours and at 24 hours, flash frozen in liquid nitrogen, and stored at À80 C until fluorimetric analysis (n ¼ 2).
Statistical Analyses
Statistical analyses of planktonic and biofilm data were performed using 1-way analysis of variance and Kruskal-Wallis tests. The level of significance was represented on graphs using the following star rating: *P .05; **P .01; ***P .001. Error bars on graphs represent AE1 standard deviation (SD).
Results

Synthetic ROþ Demonstrates Antimicrobial Activity Against Planktonic MRSA and MSSA
Both SurgihoneyRO TM and the novel synthetic honeyequivalent product showed antimicrobial activity against planktonic S. aureus (Figure 1 ). Treatment of S. aureus MRSA1 and MSSA1 strains with a range of SurgihoneyRO TM concentrations resulted in an identical MIC of 383 g/L for both strains. When treated with the same concentrations of the synthetic honey-equivalent product (Synthetic ROþ), these strains were shown to have MICs lower than those of the original SurgihoneyRO TM product with MICs of the MRSA1 and MSSA1 strains being 192 g/L and 128 g/L, respectively. In comparison, the synthetic honey-equivalent product lacking enzymatic activity (Synthetic ROÀ) did not inhibit planktonic growth of either strain, instead reducing growth only when treated with >64 g/L (MRSA1) or >6 g/L (MSSA1).
Synthetic ROþ Reduces MRSA and MSSA Biofilm Viability but Increases Biomass
Treatment of established 48-hour S. aureus MRSA1 and MSSA1 biofilms revealed that treatment with the Synthetic ROþ product for 24 hours reduced biofilm viability in both instances (Figure 2(A) and (B) ). A log-fold reduction in viability was observed when S. aureus MRSA1 biofilms were treated with 53 and 71 g/L (P ¼ .0079) and a 2-log reduction when treated with 142 g/L (P ¼ .0159). In comparison, only a log-fold reduction was observed when S. aureus MSSA1 biofilms were treated with 36 to 142 g/L (P .05). By comparison, treatment with Synthetic ROÀ had no effect on viability of biofilms formed by either strain (Figure 2(A) and (B) ). Treatment of S. aureus MRSA1 biofilms with either 36 to 71 g/L of Synthetic ROþ or Synthetic ROÀ for 24 hours resulted in a significant increase in overall biofilm biomass (P .05), while all concentrations tested (7-142 g/L) significantly increased the biomass of S. aureus MSSA1 biofilms (P .05; Figure 2 (C) and (D)); 71 g/L was chosen as the treatment concentration for all subsequent assays on the basis that it caused both a log-fold reduction in viability and an increase in biomass for both the MRSA1 and MSSA1 strain. By comparison, treatment of 48-hour MRSA1 biofilms with 71 g/L SurgihoneyRO TM for 24 hours resulted in a 2-log reduction in viability and an increase in biofilm biomass similar to the Synthetic ROþ product (P .05; Figure 2(E) ). An increase in maximum biofilm thickness was also observed through confocal imaging when treating the same biofilms with 71 g/L ROþ or ROÀ for 24 hours (Figure 3(A) and (B) ).
Synthetic ROþ Reduces the Viability of Biofilms Formed by Different MRSA and MSSA Clinical Isolates
Treatment of 48 hours established biofilms formed by several clinical MRSA (n ¼ 7) and MSSA (n ¼ 5) isolates revealed that the viability of every biofilm was reduced with an average log-fold reduction observed within each group (Figure 4(A) and (B) ). A hydrogen peroxide concentration of approximately 30 lM was reached within 15 minutes of activation of the Synthetic ROþ product and was maintained for 24 hours (Figure 4(C) ).
Discussion
Both SurgihoneyRO TM and its Synthetic ROþ equivalent showed antimicrobial activity against planktonic S. aureus. This, in addition to the inactivity of the ROÀ formulation lacking glucose oxidase, suggests that the reactive oxygen species produced by glucose oxidase results in oxidative damage and S. aureus cell death. The synthetic honey-equivalent product was more efficient at inhibiting growth of both strains than honey-based SurgihoneyRO TM , which may be explained by a slight inhibition of the enzyme by other components present in natural honey.
At higher concentrations of the enzymatically inactive product (Synthetic ROÀ) for S. aureus MRSA1 strain and all concentrations for the MSSA1 strain, some inhibition of bacterial growth can be observed. S. aureus has been shown to have a range of carbohydrate transporters, including 4 glucose transporters, which enhance its ability to uptake glucose for growth, especially during infection of nonrespiratory environments within a host. 26 This evolutionary advantage could become a disadvantage at unnaturally high levels of glucose and lead to toxicity and cell damage, which would explain reduced growth.
In established biofilms, all S. aureus strains showed reduced viability due to reactive oxygen activity after 24 hours of treatment with 71 g/L of the synthetic honey-equivalent product. This is a promising result, as bacterial biofilms, including S. aureus, have been linked to CRS recurrence, chronicity, and recalcitrance. 11 If a topical application of the synthetic honey-equivalent product could disrupt existing biofilms or prevent biofilm formation, this could be used as an adjunctive treatment potentially delivered through a saline nasal rinse, thus reducing the need for systemic antibiotics and its attendant risk of antimicrobial resistance.
As part of the developmental process toward the final formulation, the increase in biomass associated with treatment of established S. aureus MRSA1 and MSSA1 biofilms with the synthetic honey-equivalent will require further investigation. This could be caused by the formulation characteristics or by other factors such as osmotic stress levels. Future studies will also assess the response of human cells and evaluate the cytotoxicity profile of the synthetic honey-equivalent product using human primary tissues. This will enable us to assess the product in a more complex and biologically relevant environment. The final phase will be validation of these results in a clinical setting using a proof of concept clinical trial.
With the increasing burden of infections caused by antibiotic-resistant bacteria on modern health care, 27 it is now more important than ever to develop new, efficient ways of preventing and treating bacterial infections. This study is the first report of antibacterial activity of SurgihoneyRO TM and a novel synthetic honeyequivalent antimicrobial product against CRS-related mucosal MSSA and MRSA strains. The results highlight the potential of the reactive oxygen platform for use in developing novel adjunctive therapies in CRS, particularly in recalcitrant biofilm-mediated disease. Apart from treatment of biofilm-related respiratory diseases, it has been suggested that formulations containing reactive oxygen species, such as the novel synthetic honeyequivalent product, could also be useful in treatment of skin and soft tissue infections, care of postoperative surgical sites, prophylaxis of prosthetic joints infections, and in chronic recurrent multidrug-resistant cystitis. 28 
